Discovery and evaluation of inhibitors of human ceramidase

Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, Charles Smith

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation. Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation. Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs. In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small molecule library and describe the synthesis of a more potent analogue (Ceranib-2). In a cell-based assay, both compounds were found to inhibit cellular ceramidase activity toward an exogenous ceramide analogue, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death. In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity. These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.

Original languageEnglish (US)
Pages (from-to)2052-2061
Number of pages10
JournalMolecular cancer therapeutics
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Ceramidases
Ceramides
Sphingosine
Small Molecule Libraries
Neoplasms
Paclitaxel
Cell Cycle Checkpoints
Drug Resistance
Human Activities
Pharmaceutical Preparations
Cell Death
Cell Proliferation
Radiation
Survival
Enzymes
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Draper, Jeremiah M. ; Xia, Zuping ; Smith, Ryan A. ; Zhuang, Yan ; Wang, Wenxue ; Smith, Charles. / Discovery and evaluation of inhibitors of human ceramidase. In: Molecular cancer therapeutics. 2011 ; Vol. 10, No. 11. pp. 2052-2061.
@article{b843791f79294cc2b58fdbb33166e1ea,
title = "Discovery and evaluation of inhibitors of human ceramidase",
abstract = "The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation. Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation. Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs. In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small molecule library and describe the synthesis of a more potent analogue (Ceranib-2). In a cell-based assay, both compounds were found to inhibit cellular ceramidase activity toward an exogenous ceramide analogue, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death. In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity. These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.",
author = "Draper, {Jeremiah M.} and Zuping Xia and Smith, {Ryan A.} and Yan Zhuang and Wenxue Wang and Charles Smith",
year = "2011",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-11-0365",
language = "English (US)",
volume = "10",
pages = "2052--2061",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Discovery and evaluation of inhibitors of human ceramidase. / Draper, Jeremiah M.; Xia, Zuping; Smith, Ryan A.; Zhuang, Yan; Wang, Wenxue; Smith, Charles.

In: Molecular cancer therapeutics, Vol. 10, No. 11, 01.11.2011, p. 2052-2061.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery and evaluation of inhibitors of human ceramidase

AU - Draper, Jeremiah M.

AU - Xia, Zuping

AU - Smith, Ryan A.

AU - Zhuang, Yan

AU - Wang, Wenxue

AU - Smith, Charles

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation. Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation. Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs. In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small molecule library and describe the synthesis of a more potent analogue (Ceranib-2). In a cell-based assay, both compounds were found to inhibit cellular ceramidase activity toward an exogenous ceramide analogue, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death. In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity. These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.

AB - The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a critical role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation. Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation. Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs. In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small molecule library and describe the synthesis of a more potent analogue (Ceranib-2). In a cell-based assay, both compounds were found to inhibit cellular ceramidase activity toward an exogenous ceramide analogue, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death. In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity. These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.

UR - http://www.scopus.com/inward/record.url?scp=81055124269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055124269&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0365

DO - 10.1158/1535-7163.MCT-11-0365

M3 - Article

VL - 10

SP - 2052

EP - 2061

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -